This Master Class program is a global initiative of the PACE-CME foundation with a particular focus on issues and opportunities in cardiovascular risk and lipid management in high risk patients.

Agenda & Faculty

Cardiovascular Disease: The ongoing journey to manage the risk John E Deanfield, MD – University College London, United Kingdom

Managing CV Risk in Russia: How well are we doing and where can we improve? - Svetlana Shalnova, MD – Moscow, Russia

Case discussion 1 - Practical challenges in CV risk management: When to start intervening in CVD? - Oksana Drapkina, MD – Deputy Director at the Russian National Research Center for Preventive Medicine, Moscow, Russia

Managing lipids: Integrating novel insights with gold standard therapies - David Waters, MD – University of California, San Francisco, USA

New European guidance in lipid management: How to deal with international guidelines? - Kees Hovingh, MD – Academic Medical Center, Amsterdam, The Netherlands

CV Risk guidelines for Russia: What and how to follow? - Andrey Susekov MD – Central Research Laboratory, Academy of Postgraduate Education, Moscow, Russia

Case discussion 2 - Practical challenges in CV risk management: managing risk or risk factors? - Igor Sergienko, MD – Cardiology Research Complex, Moscow, Russia

Blood pressure: How do recent trial outcomes impact our hypertension management? - John E Deanfield, MD – University College London, United Kingdom

Case discussion 3 - Practical challenges in CV risk management: Managing patients with comorbidities - Alexandra Konradi, MD – Federal Almazov North-West Medical Research Centre, St Petersburg, Russia

CVD & the kidney: Implications for therapy - Kees Hovingh, MD – Academic Medical Center, Amsterdam, The Netherlands

CVD & Stroke: Understanding the relation and impact on risk management - David Waters, MD – University of California, San Francisco, USA

T2DM & CVD: An update on new strategies improving outcomes - John E Deanfield, MD – University College London, United Kingdom

**Novel approaches to target lipids: What will impact practice in the upcoming years? - Kees Hovingh, MD – Academic Medical Center, Amsterdam, The Netherlands

Educational information

The overall educational objectives of the Cardiovascular Master Class were to:

• review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk in Russia
• review new data on the pathophysiology of coronary artery disease and stroke and its relevance to treatment strategies and outcomes
• understand the medical need for intensive lipid and hypertension management in patients at high CV risk, such as DM and metabolic syndrome.
• understand the pharmacologic and clinical rationale for various treatment options in the patients with increased CV risk and integrate scientific evidence from key clinical trials into clinical practice
• Develop a consensus on practical guidelines for day-to-day management of high risk patients

CME accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of Russian Ministry of Health (Order # 82 from 18.02.2013) through the providership of Russian Cardiology Society and Russian CME Botkin Society is accredited by the the Coordination Council for Continuing Medical and Pharmaceutical to provide continuing medical education for physicians, granting 9 credits

Funding

The conference was sponsored by an unrestricted educational grant provided by Pfizer Europe